EVER SUPREME BIO TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 207 TWD | -2.13% |
|
+3.50% | +5.88% |
| Sales 2022 | 627.51 20.43K 52.32K | Sales 2023 | 758.39 24.69K 63.23K | Capitalization | 14.34B 467B 1,195B |
|---|---|---|---|---|---|
| Net income 2022 | 201M 6.54B 16.76B | Net income 2023 | 539M 17.55B 44.94B | EV / Sales 2022 | 2,19,48,957 x |
| Net cash position 2022 | 1.25B 40.75B 104B | Net cash position 2023 | 1.33B 43.27B 111B | EV / Sales 2023 | 1,71,52,867 x |
| P/E ratio 2022 |
75.3
x | P/E ratio 2023 |
27.1
x | Employees | - |
| Yield 2022 |
0.9% | Yield 2023 |
1.79% | Free-Float | 60.34% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.13% | ||
| 1 week | +3.50% | ||
| Current month | -4.83% | ||
| 1 month | -4.83% | ||
| 3 months | +4.28% | ||
| 6 months | +0.49% | ||
| Current year | +5.88% |
1 week
201.50
218.00
1 month
198.00221.00
Current year
191.00229.00
1 year
170.00229.00
3 years
140.95407.15
5 years
75.02421.62
10 years
49.19421.62
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Liang Huang
CEO | Chief Executive Officer | - | 01/17/01 |
Pai Chin Li
DFI | Director of Finance/CFO | - | 18/17/18 |
Wei Cheng Hsu
CTO | Chief Tech/Sci/R&D Officer | - | 04/19/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chin Lung Chen
BRD | Director/Board Member | - | 13/19/13 |
Shih Chun Ho
BRD | Director/Board Member | 59 | 26/18/26 |
Pei Chun Chen
BRD | Director/Board Member | - | 26/18/26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 207 | -2.13% | 1,436,577 |
| 25/24/25 | 211.5 | +3.68% | 749,862 |
| 24/24/24 | 204 | -0.24% | 506,787 |
| 23/24/23 | 204.5 | +2.00% | 205,470 |
| 22/24/22 | 200.5 | +0.25% | 328,455 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.88% | 465M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6712 Stock
